Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants

被引：316

作者：

Hicks, J. K. ^{[1
]}

Swen, J. J. ^{[2
]}

Thorn, C. F. ^{[3
]}

Sangkuhl, K. ^{[3
]}

Kharasch, E. D. ^{[4
]}

Ellingrod, V. L. ^{[5
,6
]}

Skaar, T. C. ^{[7
]}

Mueller, D. J. ^{[8
,9
]}

Gaedigk, A. ^{[10
]}

Stingl, J. C.

机构：

[1] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA

[2] Leiden Univ, Med Ctr, Dept Clin Pharm & Toxicol, Leiden, Netherlands

[3] Stanford Univ, Dept Genet, Stanford, CA 94305 USA

[4] Washington Univ, Dept Anesthesiol, Div Clin & Translat Res, St Louis, MO USA

[5] Univ Michigan, Coll Pharm, Dept Clin Social & Adm Sci, Ann Arbor, MI 48109 USA

[6] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI USA

[7] Indiana Univ Sch Med, Dept Med, Div Clin Pharmacol, Indianapolis, IN USA

[8] Univ Toronto, Neurogenet Sect, Ctr Addict & Mental Hlth, Toronto, ON, Canada

[9] Univ Toronto, Dept Psychiat, Toronto, ON, Canada

[10] Childrens Mercy Hosp & Clin, Div Pediat Pharmacol & Med Toxicol, Kansas City, MO USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2013年 / 93卷 / 05期

基金：

美国医疗保健研究与质量局; 加拿大健康研究院; 美国国家卫生研究院;

关键词：

CYP2C19-ASTERISK-17; ALLELE; PSYCHIATRIC-PATIENTS; CLOPIDOGREL THERAPY; NEUROPATHIC PAIN; AMITRIPTYLINE; NORTRIPTYLINE; METABOLISM; KINETICS; UPDATE; PLASMA;

D O I：

10.1038/clpt.2013.2

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Polymorphisms in CYP2D6 and CYP2C19 affect the efficacy and safety of tricyclics, with some drugs being affected by CYP2D6 only, and others by both polymorphic enzymes. Amitriptyline, clomipramine, doxepin, imipramine, and trimipramine are demethylated by CYP2C19 to pharmacologically active metabolites. These drugs and their metabolites, along with desipramine and nortriptyline, undergo hydroxylation by CYP2D6 to less active metabolites. Evidence from published literature is presented for CYP2D6 and CYP2C19 genotype-directed dosing of tricyclic antidepressants.

引用

页码：402 / 408

页数：7

共 40 条

[1]

[Anonymous], PRACT GUID TREATM PA

[2] EXTREMELY RAPID HYDROXYLATION OF DEBRISOQUINE - A CASE-REPORT WITH IMPLICATION FOR TREATMENT WITH NORTRIPTYLINE AND OTHER TRICYCLIC ANTIDEPRESSANTS [J].

BERTILSSON, L ;

ABERGWISTEDT, A ;

GUSTAFSSON, LL ;

NORDIN, C .

THERAPEUTIC DRUG MONITORING, 1985, 7 (04) :478-480

[3]

BERTILSSON L, 1981, LANCET, V1, P560

[4] THE NONLINEAR KINETICS OF DESIPRAMINE AND 2-HYDROXYDESIPRAMINE IN PLASMA [J].

COOKE, RG ;

WARSH, JJ ;

STANCER, HC ;

REED, KL ;

PERSAD, E .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1984, 36 (03) :343-349

[5] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype [J].

Crews, K. R. ;

Gaedigk, A. ;

Dunnenberger, H. M. ;

Klein, T. E. ;

Shen, D. D. ;

Callaghan, J. T. ;

Kharasch, E. D. ;

Skaar, T. C. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 (02) :321-326

[6] Steady state plasma levels of nortriptyline and its 1.0-hydroxy metabolite: Relationship to the CYP2D6 genotype [J].

Dahl, ML ;

Bertilsson, L ;

Nordin, C .

PSYCHOPHARMACOLOGY, 1996, 123 (04) :315-319

[7] 10-hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CΥP2D6 genes [J].

Dalén, P ;

Dahl, ML ;

Ruiz, MLB ;

Nordin, J ;

Bertilsson, L .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (04) :444-452

[8] Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients [J].

de Vos, A. ;

van der Weide, J. ;

Loovers, H. M. .

PHARMACOGENOMICS JOURNAL, 2011, 11 (05) :359-367

[9] Pharmacologic management of neuropathic pain: Evidence-based recommendations [J].

Dworkin, Robert H. ;

O'Connor, Alec B. ;

Backonja, Miroslav ;

Farrar, John T. ;

Finnerup, Nanna B. ;

Jensen, Troels S. ;

Kalso, Eija A. ;

Loeser, John D. ;

Miaskowski, Christine ;

Nurmikko, Turo J. ;

Portenoy, Russell K. ;

Rice, Andrew S. C. ;

Stacey, Brett R. ;

Treede, Rolf-Detlef ;

Turk, Dennis C. ;

Wallace, Mark S. .

PAIN, 2007, 132 (03) :237-251

[10] STEADY-STATE KINETICS OF FLUOXETINE AND AMITRIPTYLINE IN PATIENTS TREATED WITH A COMBINATION OF THESE DRUGS AS COMPARED WITH THOSE TREATED WITH AMITRIPTYLINE ALONE [J].

ELYAZIGI, A ;

CHALEBY, K ;

GAD, A ;

RAINES, DA .

JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 35 (01) :17-21

← 1 2 3 4 →